Overview

Study Evaluating Vancomycin-Resistant Enterococci in a Hematology Unit

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To determine the impact of the restriction of the third and forth generation cephalosporins on the reduction of intestinal colonization or infection with vancomycin-resistant enterococci (VRE) in a surgical intensive care unit (SICU)
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
beta-Lactams
Lactams
Penicillanic Acid
Piperacillin
Piperacillin, Tazobactam Drug Combination
Tazobactam
Vancomycin